Tuberculosis still kills more people each year than any other infectious disease, despite decades of medical progress.
But a team of researchers from Texas A&M University and Scripps Research may have found a long-awaited breakthrough — a new drug candidate that could outsmart even the most resistant forms of the bacteria.
A fresh hope against a deadly infection
Tuberculosis, caused by Mycobacterium tuberculosis, infects millions worldwide every year and has grown increasingly resistant to existing drugs.
The new compound, called CMX410, attacks the bacteria in a way scientists have never achieved before — by targeting a crucial enzyme that the pathogen needs to build its protective outer shell.
Also read: Wildfire pollution may lead to premature births
This enzyme, known as Pks13, helps the bacteria construct its cell wall, a kind of armor that shields it from antibiotics and the immune system.
CMX410 disables this process entirely, causing the bacteria to collapse and die.
From lab to life-saving potential
After screening hundreds of chemical candidates, the research team fine-tuned CMX410 to maximize its safety, precision, and power.
When tested on 66 strains of tuberculosis, including multidrug-resistant samples from patients, the compound proved effective in nearly every case.
Also read: Study finds the eyes reflect the body’s biological age
Even better, early tests in animals showed no toxic side effects, even at high doses. That makes CMX410 one of the most promising TB candidates in decades.
Because of its targeted mechanism, it also avoids disrupting healthy gut bacteria — a common problem with traditional antibiotics.
Why this discovery matters
Drug-resistant TB is one of the world’s most urgent health threats. Current treatments can take six months or longer, requiring a cocktail of antibiotics that often cause severe side effects.
A drug like CMX410 could shorten treatment times and make therapies safer and more effective for millions of people.
Also read: New study found that exposure to artificial light can harm the heart
The researchers emphasize that more testing is needed before human trials begin, but their findings already suggest a major step toward finally controlling — and perhaps one day eradicating — tuberculosis.
A look at what’s next
The next phase of the research will focus on fine-tuning CMX410’s stability and testing it in combination with other TB drugs.
The ultimate goal: a treatment that’s not only more powerful but also simpler, safer, and shorter — giving patients a realistic chance to complete therapy and fully recover.
Article based on information from:
Texas A&M AgriLife
ScienceDaily
Nature Journal
Also read: Study finds higher hospitalization and death rates in long-term melatonin users
Also read: Chicken soup could harm your body over time